Lipid-lowering therapy: modern possibilities and real clinical practice

Lipid-lowering therapy: modern possibilities and real clinical practice

Aim. To monitor the scope and effectiveness of lipid-lowering therapy (LLT) in the out- and inpatient settings among people hospitalized at the National Medical Research Center for Therapy and Preventive Medicine.Material and methods. Retrospective analysis of randomly selected case records for Apri...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Blokhina, A. I. Ershova, A. N. Meshkov, N. M. Akhmedzhanov, A. A. Ivanova, K. A. Guseinova, S. A. Smetnev, O. A. Litinskaya, S. A. Boytsov, A. M. Drapkina
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2022-09-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	lipid-lowering therapy statins atorvastatin rosuvastatin outpatient care low-density lipoprotein cholesterol cardiovascular risk hyperlipidemia
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/3369
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

THE EFFECTIVENESS OF OUTPATIENT AND HOSPITAL LIPID-LOWERING THERAPY IN PATIENTS WITH HIGH AND VERY HIGH CARDIOVASCULAR RISK DURING 2011-2015
by: S. A. Smetnev, et al.
Published: (2017-01-01)

Lipid Clinic is an Efficacious Model of Preventive Medicine
by: A. V. Blokhina, et al.
Published: (2021-03-01)

Choosing lipid lowering statin in risk strategy of cardiovascular event prevention
by: A. Ya. Yvleva, et al.
Published: (2007-02-01)

Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
by: Sh. A. Mostafa, et al.
Published: (2018-11-01)

LIPID-LOWERING EFFICACY OF ROSUVASTATIN COMPARED WITH OTHER STATINS
by: A. N. Meshkov
Published: (2015-12-01)

Statin choice for lipid6lowering therapy: clinical pharmacology and evidence-based medicine position
by: S. V. Nedogoda
Published: (2008-02-01)

Rosuvastatin safety and efficacy in coronary heart disease patients
by: I. V. Sergienko, et al.
Published: (2006-10-01)

New perspectives in treating high-risk cardiac patients. Rosuvastain and it’s perspectives for clinical practice use
by: M. G. Bubnova
Published: (2007-12-01)

Clinical, lipid-lowering, and pleiotropic effectiveness of rosuvastatin: a review of the GALAXY programme results
by: A. N. Britov, et al.
Published: (2011-02-01)

Modern algorithms for statin therapy
by: V. A. Susekov
Published: (2023-11-01)

Serum lipids and smoking status in coronary heart disease patients treated with simvastatin
by: L. R. Gazdanova, et al.
Published: (2010-04-01)

STATINS IN CHRONIC KIDNEY DISEASE. IS THERE A DRUG OF CHOICE?
by: O. M. Drapkina, et al.
Published: (2015-12-01)

LIPID-LOWERING THERAPY IN OUTPATIENT PRACTICE (ACCORDING TO THE ARGO-2 STUDY)
by: N. M. Akhmedzhanov, et al.
Published: (2016-05-01)

EFFECT OF SIMVASTATIN ON MARKERS OF CARDIOVASCULAR RISK
by: N. V. Perova, et al.
Published: (2016-01-01)

Adherence to Statins Therapy of High and Very High Cardiovascular Risk Patients in Real Clinical Practice: Diagnostics and Possible Ways to Solve the Problem (According to the PRIORITY Observational Study)
by: S. Yu. Martsevich, et al.
Published: (2019-01-01)

Biochemical, structural and clinical analysis of statins’ pleiotropic effects
by: A. N. Britov, et al.
Published: (2009-10-01)

The possible modulatory impact of high-dose statin therapy on carotid intima-media thickness: a preliminary study
by: Tomasz K. Urbanowicz, et al.
Published: (2024-11-01)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022-01-01)

Combined lipid lowering therapy, including ezetimibe, in the post-infarction period
by: V. E. Oleynikov, et al.
Published: (2024-05-01)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA IN REAL OUTPATIENT PRACTICE (ACCORDING TO THE RECVASA REGISTRY)
by: A. I. Ershova, et al.
Published: (2015-09-01)

Muscular and Renal Safety of Ticagrelor with High-Intensity Statins: Retrospective Cohort Findings
by: Alshammari AS, et al.
Published: (2025-06-01)

Effectiveness of lipid-lowering therapy in outpatients with coronary artery disease living in a large industrial center of Eastern Siberia
by: N. G. Gogolashvili, et al.
Published: (2022-01-01)

COMPLEX ASSESSMENT OF EFFICACY OF STATINS PRESCRIBED AT MOST BY CLINICIANS
by: A. S. Sivkov, et al.
Published: (2018-06-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

METABOLIC SYSTEM OF CHOLESTEROL ELIMINATION FROM TISSUES. POSSIBILITY OF ACTIVATION ITS KEY PARTS
by: N. V. Perova, et al.
Published: (2016-01-01)

Atorvastatin blocks Sonic Hedgehog medulloblastoma progression through apoptosis
by: R.E. Gordon, et al.
Published: (2017-12-01)

Contradictions in traditional ideas about atherosclerosis and the efficacy of lipid-lowering therapy. Promising directions
by: A. P. Vasiliev, et al.
Published: (2024-08-01)

Familial hypercholesterolemia: current status of the problem, treatment, and prevention
by: S. A. Bliznyuk, et al.
Published: (2020-11-01)

Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study
by: Andrej Belančić, et al.
Published: (2025-06-01)

Association of various lipid parameters with premature coronary artery disease in men
by: A. V. Tyurina, et al.
Published: (2022-07-01)

Effectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry
by: I. A. Alekseeva, et al.
Published: (2025-08-01)

Studying the Possibility of Optimizing the Statin Therapy Algorithm in Outpatient Practice
by: D. V. Nebieridze, et al.
Published: (2020-09-01)

ESCADRA: a randomised study. Part I: lipid-lowering effectiveness, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with initial doses of statins in patients with coronary heart disease and hyperlipidemia
by: M. Yu. Zubareva, et al.
Published: (2010-12-01)

Lipid‐Lowering Therapy Use When Indicated and Subsequent Ischemic Stroke Severity
by: Barbara Gordon‐Kundu, et al.
Published: (2025-01-01)

LIPRIMAR®. FIFTEEN YEARS OF EVIDENCE
by: A. V. Susekov, et al.
Published: (2016-01-01)

Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis
by: N. E. Gavrilova, et al.
Published: (2015-11-01)

Ezetimibe potential in cardiology practice
by: A. A. Lyakishev, et al.
Published: (1970-01-01)

Study on the influence of 7-β-hydroxy-γ-aryloxypropylxanthinyl-8-thioalkanic acid derivatives on the lipid metabolism in experiment
by: I. M. Bilai, et al.
Published: (2021-06-01)

Lipid-lowering and pleiotropic effects of rosuvastatin in patients with acute myocardial infarction
by: N. A. Dzhaiani, et al.
Published: (2008-12-01)

Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01)